AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
US firms are also staring down a multi-billion dollar patent cliff of their own, prompting a yearslong buying spree.
J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.
AstraZeneca is the biggest drugmaker in Britain and its £193 billion ($253 billion) market capitalization tops the London Stock Exchange.
BMO analysts said in a note Monday they were “encouraged” that Genmab’s acquisition “could start to spur broader M&A in the sector.”
China’s pharmaceutical sector, a minor player just years ago, has revved up into a global juggernaut faster than a Fuxing high speed train.
About 5 million people are affected by idiopathic pulmonary fibrosis globally, according to the National Institutes of Health.
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its portfoilio.
A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.